Last reviewed dd mmm yyyy. Last edited dd mmm yyyy
The goal of disease modifying therapy in secondary progressive multiple sclerosis is to delay the progression of disability.
Interferon-beta1b has been shown in one randomised double blind placebo controlled multicentre trial to significantly increase the time to confirmed neurological deterioration.
Interferon-beta1b is licensed in Europe for secondary progressive MS.
NICE state (1,2):
Notes:
Reference:
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.